Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. betascreen

BETASCREEN

A Unique Pancreatic Human Beta Cells to revolutionize the Diabetes Drug Discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BETASCREEN project word cloud

Explore the words cloud of the BETASCREEN project. It provides you a very rough idea of what is the project "BETASCREEN" about.

segments    europe    outcome    maturity    patients    saving    regulatory    anti    reproducibility    jan    strategic    generating    dollars    world    predictive    technologies    industry    exceptional    academia    cutting    types    line    surprise    turnover    cell    strategy    marketed    lack    accelerate    2015    leader    1billion    secure    overcome    population    innovative    adoption    15    screening    prevents    faced    industrials    disruptive    industrial    pharmas    rentability    astrazeneca    replication    bottlenecks    pharma    cells    samples    jobs    ultimate    pharmaceutical    tornell    says    issue    generation    first    biosolutions    think    big    commercialization    substitute    betascreen    selling    univercell    decreasing    edge    pancreatic    leaders    clinical    creation    homogeneity    2021    biotech    ing    portfolio    poor    beta    models    stem    ub    scarce    avenues    110    diabetes    10    pressure    division    company    quantity    attrition    90    commercial    accessible    drug    animal    predictability    tissues    revenues    hope    human    solution    market    lines    pioneering    million    rate    coherence   

Project "BETASCREEN" data sheet

The following table provides information about the project.

Coordinator		 UNIVERCELL BIOSOLUTIONS SAS 

Organization address
address: PLACE PIERRE POTIER CENTRE PIERRE POTIER CANCEROPOLE ENTREE B
city: TOULOUSE
postcode: 31000
website: www.univercell-biosolutions.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.endocells.com/products-and-services/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERCELL BIOSOLUTIONS SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Univercell Biosolutions (UB) is a pioneering biotech company providing unique human cell models to accelerate and secure pharmaceutical products. UB is generating 1 M€ turnover in 2015 selling its first generation of human beta cell lines to 10 world pharma industry leaders. Pharmas rentability is decreasing facing to high regulatory pressure and low clinical predictability on human. The rate of clinical drug failure is about 90% and cost for marketed a new drug reach up to 1billion dollars. Early clinical predictability is a strategic issue for industrials. Jan Tornell an AstraZeneca division leader says: “The big think is that when we get into patients, we want no surprise”. Cells from human tissues samples are scarce and not accessible for Pharmas applications. Thus, Industrials developed substitute from animal with poor clinical predictability. Recently, Stem cell technologies has open new hope in providing large quantity of human cells but is still faced with major bottlenecks: lack of cell maturity (clinical predictability) and low cell population homogeneity (reproducibility) which prevents large adoption by industrials. UB has developed a portfolio of cutting edge technologies to overcome these bottlenecks. The first outcome of BETASCREEN is a disruptive pancreatic beta cell line for anti-diabetes research, with ultimate objective of replication to other cell types. The solution targets pharmaceutical, biotech, and academia. Within BETASCREEN, UB will define best commercialization strategy in coherence with market’s targeted segments and identify industrial partners for large-scale production (Phase 2) and commercialization. BETASCREEN will improve the predictive value of screening by decreasing the drug attrition rate up to 10%. Resulting cost saving for industrials could reach 100 million dollars per innovative new drug development. This will open exceptional commercial avenues for UB with revenues estimated at 15 M€ in 2021 and 110 jobs creation in Europe

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETASCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETASCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More